Juvenile idiopathic arthritis (JIA) represents a heterogeneous group of chronic inflammatory diseases affecting the joints, beginning before the age of 16 years. Systemic JIA has recently been recognized by experts as the pediatric form of Still's disease; prompt treatment, in particular IL-1 or IL-6 blockade and active screening for complications are recommended (PRES/EULAR 2024). New medications have significantly improved the long-term outcome of JIA. However, achieving and maintaining remission still remains difficult. Durable remission rate in adulthood is low, with physical disability reported in approximately half of patients. Therefore, a multidisciplinary approach and a well-coordinated transition program are essential to ensure the best long-term outcome of these patients.